Browsing Tag
Robert A. Michael
2 posts
AbbVie (ABBV) raises 2026 revenue guidance as Skyrizi and Rinvoq lift Q2 revenue to $17bn
AbbVie posted Q2 2026 revenue of $16.99 billion as Skyrizi crossed $5.5bn quarterly, but the pending $10.9bn Apogee deal trimmed 2026 adjusted EPS guidance.
August 2, 2026
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges…
February 2, 2025